JP2011506551A - Ａｍｐａ受容体増強化合物および医薬におけるその使用 - Google Patents

Ａｍｐａ受容体増強化合物および医薬におけるその使用 Download PDF

Info

Publication number
JP2011506551A
JP2011506551A JP2010538692A JP2010538692A JP2011506551A JP 2011506551 A JP2011506551 A JP 2011506551A JP 2010538692 A JP2010538692 A JP 2010538692A JP 2010538692 A JP2010538692 A JP 2010538692A JP 2011506551 A JP2011506551 A JP 2011506551A
Authority
JP
Japan
Prior art keywords
dihydro
inden
propanesulfonamide
oxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010538692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506551A5 (enExample
Inventor
ニコラ、ベルテレム
ワイ、ニョール、チャン
ジャクリーン、サンドラ、スコット
サイモン、イー．ウォード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0724783A external-priority patent/GB0724783D0/en
Priority claimed from GB0818068A external-priority patent/GB0818068D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2011506551A publication Critical patent/JP2011506551A/ja
Publication of JP2011506551A5 publication Critical patent/JP2011506551A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2010538692A 2007-12-19 2008-12-17 Ａｍｐａ受容体増強化合物および医薬におけるその使用 Withdrawn JP2011506551A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0724783A GB0724783D0 (en) 2007-12-19 2007-12-19 Compounds
GB0818068A GB0818068D0 (en) 2008-10-02 2008-10-02 Compounds
PCT/EP2008/067681 WO2009080637A1 (en) 2007-12-19 2008-12-17 Compounds which potentiate the ampa receptor and uses thereof in medicine

Publications (2)

Publication Number Publication Date
JP2011506551A true JP2011506551A (ja) 2011-03-03
JP2011506551A5 JP2011506551A5 (enExample) 2012-02-02

Family

ID=40566351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538692A Withdrawn JP2011506551A (ja) 2007-12-19 2008-12-17 Ａｍｐａ受容体増強化合物および医薬におけるその使用

Country Status (9)

Country Link
US (1) US8173820B2 (enExample)
EP (1) EP2222632A1 (enExample)
JP (1) JP2011506551A (enExample)
AR (1) AR069781A1 (enExample)
CL (1) CL2008003773A1 (enExample)
PE (1) PE20091086A1 (enExample)
TW (1) TW200940491A (enExample)
UY (1) UY31544A1 (enExample)
WO (1) WO2009080637A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523656A (ja) * 2008-06-06 2011-08-18 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ受容体モジュレーターとしてのインダン誘導体
JP2016074644A (ja) * 2014-10-08 2016-05-12 田岡化学工業株式会社 スピロビフルオレン骨格を有するジオール化合物およびその製造方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0821166D0 (en) * 2008-11-19 2008-12-24 Glaxo Group Ltd Compounds
US8633237B2 (en) 2009-04-09 2014-01-21 Merck Sharp & Dohme B.V. Indane derivatives
WO2012137982A2 (en) 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525099B1 (en) * 1998-07-31 2003-02-25 Eli Lilly And Company N-substituted sulfonamide derivatives
AU2005270377A1 (en) * 2004-08-09 2006-02-16 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
GB0417709D0 (en) * 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523656A (ja) * 2008-06-06 2011-08-18 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ受容体モジュレーターとしてのインダン誘導体
JP2016074644A (ja) * 2014-10-08 2016-05-12 田岡化学工業株式会社 スピロビフルオレン骨格を有するジオール化合物およびその製造方法

Also Published As

Publication number Publication date
EP2222632A1 (en) 2010-09-01
WO2009080637A1 (en) 2009-07-02
US20110021578A1 (en) 2011-01-27
UY31544A1 (es) 2009-07-17
CL2008003773A1 (es) 2010-03-05
AR069781A1 (es) 2010-02-17
PE20091086A1 (es) 2009-08-23
TW200940491A (en) 2009-10-01
US8173820B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
US7649004B2 (en) Pyridine derivatives
US8153658B2 (en) Piperidine derivative or salt thereof
WO2012007861A1 (en) N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
JP4901735B2 (ja) グルタミン酸受容体を強化する化合物および医学におけるその使用
JP2019077713A (ja) ＮＲ２ＢのＮ−アルキルアリール−５−オキシアリール−オクタヒドロ−シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター
CN105130957A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
US8173820B2 (en) Compounds which potentiate the AMPA receptor and uses thereof in medicine
NL1031335C2 (nl) Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
AU2006310215A1 (en) Pyrazine derivatives as sodium channel modulators for the treatment of pain
EP3468964B1 (en) Modulators of soce, compositions, and uses thereof
EP1848695B1 (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
WO2010066658A1 (en) Compounds which potentiate the ampa receptor and uses thereof in medicine
JP2010517926A (ja) グルタミン酸受容体を増強する、統合失調症の治療に有用な４−フェニル−３−（２−プロピルスルホニルアミノ）テトラヒドロフラン誘導体
KR20120101551A (ko) Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸
WO2010057865A1 (en) N- inden- 2 -yl- isopropylsulfonamides as ampa receptor potentiators
JP2008509181A (ja) グルタミン酸受容体を強化する化合物および医学におけるその使用
KR20180053357A (ko) 2,3,4,5-테트라히드로피리딘-6-아민 유도체
KR20120097400A (ko) Ｍｇｌｕｒ５ 리셉터의 알로스테릭 조절자로서의 비사이클릭 티아졸
US20090170902A1 (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
BG103685A (bg) Хиноксалиндиони
CN111343978A (zh) 新型盐
WO2008110566A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
RU2575168C2 (ru) Арил-замещенные карбоксамидные производные в качестве блокаторов кальциевых или натриевых каналов
WO2010037760A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130423

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20130507